![A medic at Burjeel Hospital in central Abu Dhabi holds a dose of a vaccine developed by Chinese drug maker Sinopharm. Victor Besa / The National](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/25YRTZAW7SO5Q25ZGPHLQ7XCGQ.jpg?smart=true&auth=59c5fa311def80229972dfb333343a7a79cc11879ac89433710eed91136e7452&width=400&height=225)
A medic at Burjeel Hospital in central Abu Dhabi holds a dose of a vaccine developed by Chinese drug maker Sinopharm. Victor Besa / The National
A medic at Burjeel Hospital in central Abu Dhabi holds a dose of a vaccine developed by Chinese drug maker Sinopharm. Victor Besa / The National
Burjeel IPO: UAE healthcare provider raises $300m from oversubscribed offering
Offering was more than 29 times oversubscribed, drawing strong demand from the UAE and region, with total gross demand at more than $8.7bn